These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
    Author: Chen PT, Liaw CC.
    Journal: Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417.
    Abstract:
    BACKGROUND: This study examined whether different ondansetron dosing schedules plus dexamethasone influenced antiemetic efficacy during multiple cycles of cisplatin-based chemotherapy (CT). Antiemetic activities between previous CT and subsequent cycles were compared. METHODS: The cross-over study involved 424 patients. Arm A, three doses of 8 mg ondansetron given intravenously (IV) at 4-hourly intervals plus dexamethasone 20 mg IV at the start of CT, followed by dexamethasone 5 mg IV every 12 hours. Arm B, as arm A but the three doses of 8 mg ondansetron were given at 24-hourly intervals. For those with complete protection from emesis in both arms, a single dose of 8 mg ondansetron (arm C) was tried during the following CT. Once complete protection of emesis could not be maintained, arm A regimens were administered in the subsequent cycles of CT. RESULTS: There were 384, 377 and 147 patients in arm A, arm B and arm C, respectively. Complete control of acute and delayed nausea/vomiting obtained in arm A were 91.4%/94.8% and 59.6%/70.1%, and in arm B were 90.4%/92.3% and 61.3% 72.7%. There was no significant difference in antiemetic efficacy between both arms. Decreased incidence of and delayed onset of nausea on day 2 were observed in arm B (p = 0.002). The emetic severity during previous CT correlated significantly with those of the subsequent CT. The complete control of nausea/vomiting was maintained in 81.6%/72.1% of arm C patients during the following 3rd-6th cycles of CT. CONCLUSION: No difference in antiemetic efficacy was shown when a triple 8 mg dose of ondansetron was given at 4-hourly intervals or at 24-hourly intervals. However, the latter improved nausea on day 2. A single 8 mg dose of ondansetron can maintain antiemetic efficacy in the majority of complete responders in arm A and arm B.
    [Abstract] [Full Text] [Related] [New Search]